Clinical Trials – Page 4 – media

Innovative New Method To Fight Cancer

The research study revealed that tumor growth could be reduced by targeting the expression of Beta3-integrin along with microtubule-targeting agents (MTAs) chemotherapy. Beta3-integrin was the better anti-angiogenic target since it was expressed in tumor blood vessels, unlike normal cells.
- Source: Ddu
- 718
- May 29, 2018
cancer Clinical Trials
LifePlus announces glucose monitoring wearable

The company announced that the innovative product, whose technological details are not known yet, is undergoing clinical trials in five cities across the world. The patent-pending invention is based on open standards software and cloud-based analytics. The system gives users real-time notifications and cloud-based AI solutions.
- Source: Ddu
- 995
- May 18, 2018
Clinical Trials mHealth wearables
Discovery of anti-stroke compound

A research team led by Yokohama City University and Toyama Chemical Co Ltd in Japan has developed a small compound named edonerpic maleate that showed enhanced recovery of motor function after brain damage in animal trials.
- Source: Ddu
- 604
- May 18, 2018
Clinical Trials Researches stroke
EIP Pharma bags $20.5M to support Alzheimer’s drug through phase 2

EIP Pharma raised $20.5 million series B funding to support Neflamapimod, the phase 2b program of its Alzheimer treatment. The funding is also to build the team and to support other research studies related to central nervous system disorders.
- Source: Ddu
- 581
- May 18, 2018
Alzheimer's disease Clinical Trials
NHS England moves to fast-track clinical trials

NHS England has unveiled new processes designed to fast track clinical trials undertaken across the NHS, and boost access for patients.
- Source: pharmatimes
- 613
- May 9, 2018
Clinical Trials NHS
Hanmi Pharma gives up on development of lung cancer drug Olita

South Korean pharmaceutical firm Hanmi Pharmaceutical is expected to cease development of Olita, a lung cancer treatment, following its slow progress in clinical trials and cancellation of licensing deals with foreign drug makers.
- Source: koreaher
- 2,371
- April 20, 2018
Clinical Trials Company Insights Olita
Drugs for Neglected Diseases initiative and Pharco Pharmaceuticals to test affordable hepatitis C regimen with support of Malaysian and Thai governments

Potentially pan-genotypic combination of ravidasvir and sofosbuvir to be tested in Malaysia and Thailand with target price of under $300
- Source: dndi
- 672
- April 17, 2018
Clinical Trials hepatitis C
Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for LYNPARZA®(olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018.
- Source: businesswire
- 897
- April 17, 2018
AstraZeneca breast cancer Clinical Trials Merk
Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene on March 22nd, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University Medical Center.
- Source: finance.yahoo
- 636
- April 16, 2018
Clinical Trials DMD
KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells

Based on the recommendation of the DMC, the trial will continue to evaluate progression-free survival (PFS), which is a secondary endpoint. Results from KEYNOTE-042 will be presented at an upcoming medical meeting and submitted to regulatory authorities worldwide.
- Source: finance.yahoo
- 690
- April 10, 2018
Clinical Trials keytruda Merck NSCLC

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.